FrancophonIA/ELRC3.0 huggingface dataset:
English: Sorafenib therapy should be discontinued (see section 4.8).
Slovenian: Zdravljenje s sorafenibom je treba prenehati (glejte poglavje 4.8).
English: Tablet coating: hypromellose, macrogol, titanium dioxide (E 171), ferric oxide red (E 172).
Slovenian: Obloga tablete: hipromeloza, makrogol, titanov dioksid (E 171), rdeči železov oksid (E 172).
English: Lipase increased * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 ** The aetiology of hypophosphatemia associated with sorafenib is not known.
Slovenian: Preiskave zvečana vrednost amilaze zvečana vrednost lipaze * terminološko poenoteni kriteriji za neželene učinke (CTCAE - Common Terminology Criteria for Adverse Events), različica 3,0 ** vzrok hipofosfatemije, povezane z uporabo sorafeniba, ni znan.
English: Sorafenib was not genotoxic in the Ames test or in the in vivo mouse micronucleus assay.
Slovenian: Sorafenib ni bil genotoksičen pri Amesovem testu, niti in vivo v poskusu na mišjih mikronukleusih.
English: Blood glucose levels in diabetic patients should be checked regularly in order to assess if anti-diabetic medicinal product's dosage needs to be adjusted.
Slovenian: Pri bolnikih s sladkorno boleznijo je treba redno preverjati vrednosti glukoze v krvi, da se oceni, ali je treba prilagoditi odmerke antidiabetikov.
English: Hypertension was usually mild to moderate, occurred early in the course of treatment, and was amenable to management with standard antihypertensive therapy.
Slovenian: Ponavadi je bila blaga do zmerno huda, pojavila se je na začetku zdravljenja s sorafenibom; za zdravljenje so zadostovali standardni antihipertenzivi.
English: Therefore, clinical pharmacokinetic interactions of sorafenib with substrates of these enzymes are unlikely.
Slovenian: Zaradi tega so klinične farmakokinetične interakcije sorafeniba s substrati omenjenih encimov malo verjetne.
English: Patients were included in the study if they experienced progression within 14 months of enrollment and had DTC refractory to radioactive iodine (RAI).
Slovenian: Bolniki so bili v študijo vključeni, če se je napredovanje pojavilo v zadnjih 14 mesecih pred vključitvijo in če so imeli diferencirani karcinom ščitnice, odporen na radioaktivni jod (RAIradioactive iodine).
English: Bayer Hungária KFT Tel.:+36 14 87-41 00
Slovenian: Magyarország Bayer Hungária KFT Tel:+36 14 87-41 00
English: In a clinical pharmacology study, QT/QTc measurements were recorded in 31 patients at baseline (pre-treatment) and post-treatment.
Slovenian: V študijah klinične farmakologije, so opravili meritve intervala QT/QTc pri 31 bolnikih na začetku in na koncu zdravljenja.
English: Cardiac ischaemia and/or infarction
Slovenian: Srčna ishemija in/ali infarkt
English: These data suggest that sorafenib at the recommended dose of 400 mg twice daily may not be an in vivo inhibitor of CYP2B6 or CYP2C8.
Slovenian: Ti podatki kažejo, da sorafenib v priporočenih odmerkih 400 mg dvakrat na dan in vivo verjetno ne zavira CYP2B6 in CYP2C8.
English: - If you are taking irinotecan or are given docetaxel, which are also medicines for cancer.
Slovenian: - če dobivate irinotekan ali docetaksel, ki sta prav tako zdravili za zdravljenje rakavih bolezni.
English: Nexavar 200 mg film-coated tablets are red and round with the Bayer cross on one side and “200” on the other side.
Slovenian: Nexavar 200 mg filmsko obložene tablete so rdeče, okrogle z znakom Bayer na eni in oznako »200« na drugi strani.
English: - Fertility.
Slovenian: - Plodnost.
English: The pharmacokinetics of carboplatin were unaffected.
Slovenian: Na farmakokinetiko karboplatina ne vpliva.
English: Sorafenib conjugates may be cleaved in the gastrointestinal tract by bacterial glucuronidase activity, allowing reabsorption of unconjugated active substance.
Slovenian: Konjugati sorafeniba se lahko s pomočjo bakterijske glukuronidazne aktivnosti v prebavilih razcepijo, kar omogoča reabsorpcijo nekonjugirane učinkovine.
English: Typical changes consisted of signs of degeneration and retardation in testes, epididymides, prostate, and seminal vesicles of rats.
Slovenian: Značilne spremembe so bile degeneracija in retenca testisov, nadmodka, prostate in semenskih mešičkov podgan.
English: No subject showed a QTcB or QTcF >500 msec during the post-treatment ECG monitoring (see section 4.4).
Slovenian: Po koncu zdravljenja ni bil v EKG pri nobenem bolniku interval QTcB ali QTcF > 500 msec (glejte poglavje 4.4).
English: Sorafenib has been shown to be embryotoxic and teratogenic when administered to rats and rabbits at exposures below the clinical exposure.
Slovenian: Sorafenib je deloval embriotoksično in teratogeno pri podganah in kuncih, kadar je bila izpostavljenost manjša od klinične izpostavljenosti.
English: Further information on selected adverse drug reactions
Slovenian: Dodatni podatki o izbranih neželenih učinkih
English: Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96 % of the dose was recovered within 14 days, with 77 % of the dose excreted in faeces, and 19 % of the dose excreted in urine as glucuronidated metabolites.
Slovenian: Po peroralnem zaužitju 100 mg raztopine sorafeniba so po 14 dneh zbrali 96 % odmerka; 77 % se ga je izločilo z blatom, 19 % pa s sečem v obliki glukuronidnih presnovkov.
English: Use sorafenib with caution in patients who have, or may develop prolongation of QTc, such as patients with a congenital long QT syndrome, patients treated with a high cumulative dose of anthracycline therapy, patients taking certain anti-arrhythmic medicines or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia.
Slovenian: Pri uporabi sorafeniba je potrebna previdnost pri bolnikih, ki imajo ali pri katerih se lahko podaljša interval QTc, kot npr. pri bolnikih s prirojenim sindromom dolgega intervala QT, bolnikih zdravljenih z velikimi skupnimi odmerki antraciklinov, bolnikih, ki jemljejo določene antiaritmike ali druga zdravila, ki podaljšajo interval QT in bolnikih z motnjami elektrolitskega ravnovesja kot so hipokaliemija, hipokalciemija ali hipomagneziemija.
English: These data suggest that clinical pharmacokinetic interactions of sorafenib with CYP3A4 inhibitors are unlikely.
Slovenian: Ti podatki kažejo, da so klinične farmakokinetične interakcije sorafeniba in zaviralcev CYP3A4 malo verjetne.
English: Nexavar is indicated for the treatment of hepatocellular carcinoma (see section 5.1).
Slovenian: Zdravilo Nexavar je indicirano za zdravljenje bolnikov s karcinomom jetrnih celic (glejte poglavje 5.1).
English: This study, conducted in China, Korea and Taiwan confirmed the findings of Study 3 with respect to the favourable benefit-risk profile of sorafenib (HR (OS): 0.68, p = 0.01414).
Slovenian: Študija, ki je potekala na Kitajskem, v Koreji in Tajvanu je potrdila ugotovitve iz študije 3; razmerje med koristmi in tveganji je bilo v prid uporabi sorafeniba (razmerje ogroženosti (celokupno preživetje): 0,68, p = 0,01414).
English: After one 28-day treatment cycle, at the time of maximum concentration of sorafenib, QTcB was prolonged by 4 ±19 msec and QTcF by 9 ±18 msec, as compared to placebo treatment at baseline.
Slovenian: Po 28-dnevnem ciklusu zdravljenja, je bil v času največje koncentracije sorafeniba, interval QTcB daljši za 4 + 19 msec in interval QTcF za 9 + 18 msec kot pri tistih, ki so na začetku zdravljenja prejemali placebo.
English: CYP1A2 and CYP3A4 activities were not altered after treatment of cultured human hepatocytes with sorafenib, indicating that sorafenib is unlikely to be an inducer of CYP1A2 and CYP3A4.
Slovenian: Aktivnost CYP1A2 in CYP3A4 se po uporabi sorafeniba in vitro na gojenih humanih jetrnih celicah ni spremenila, kar kaže, da je malo verjetno, da bi sorafenib induciral CYP1A2 in CYP3A4.
English: Changes consisted in irregular thickening of the femoral growth plate, hypocellularity of the bone marrow next to the altered growth plate and alterations of the dentin composition.
Slovenian: Spremembe so bile povezane z nepravilnostmi v zakostenevanju rastnega hrustanca stegnenice, hipocelularnostjo kostnega mozga pri spremembah rastnega hrustanca in s strukturnimi spremembami zobnega dentina.
English: Bayer Vital GmbH Tel: +49 (0)214-30 513 48
Slovenian: Deutschland Bayer Vital GmbH Tel: +49 (0)214-30 513 48
English: Other inducers of CYP3A4 activity and/or glucuronidation (e.g. Hypericum perforatum also known as St. John's wort, phenytoin, carbamazepine, phenobarbital, and dexamethasone) may also increase metabolism of sorafenib and thus decrease sorafenib concentrations.
Slovenian: Drugi induktorji aktivnosti CYP3A4 in/ali glukuronidacije (npr. Hypericum perforatum, znana tudi kot šentjanževka, fenitoin, karbamazepin, fenobarbital in deksametazon), lahko zvečajo presnovo sorafeniba in tako zmanjšajo njegovo koncentracijo.
English: When given with a high-fat meal sorafenib absorption was reduced by 30 % compared to administration in the fasted state.
Slovenian: Če je bil sorafenib zaužit hkrati z zelo mastno hrano, je bila njegova absorpcija v primerjavi s tisto po zaužitju na tešče manjša za 30 %.
English: These data indicate no need for dose adjustments when paclitaxel and carboplatin are co-administered with sorafenib with a 3-day break in sorafenib dosing (two days prior to and on the day of paclitaxel/carboplatin administration).
Slovenian: Ti podatki kažejo, da odmerka ni treba prilagajati, če se paklitaksel in karboplatin uporabljata sočasno s sorafenibom, s 3-dnevnimi prekinitvami pri odmerjanju sorafeniba (dva dni pred in na dan aplikacije paklitaksela/karboplatina).
English: The clinical significance of these small to modest increases in capecitabine and 5-FU exposure when co-administered with sorafenib is unknown.
Slovenian: Klinična pomembnost tega majhnega do zmernega zvečanja izpostavljenosti kapecitabinu in 5-FU, pri sočasni uporabi s sorafenibom, ni znana.
English: DTC refractory to RAI was defined as having a lesion without iodine uptake on a RAI scan, or receiving cumulative RAI ≥ 22.2 GBq, or experiencing a progression after a RAI treatment within 16 months of enrollment or after two RAI treatments within 16 months of each other.
Slovenian: Diferencirani karcinom ščitnice, odporen na radioaktivni jod, je bil opredeljen kot lezija brez privzema joda na slikanju z radioaktivnim jodom, ali kumulativna izpostavljenost RAI ≥ 22,2 GBq ali napredovanje po zdravljenju z radioaktivnim jodom v zadnjih 16 mesecih pred vključitvijo ali po dveh zdravljenjih z radioaktivnim jodom v razmaku 16 mesecev.
English: Not known: frequency cannot be estimated from the available data - impaired brain function that can be associated with e.g. drowsiness, behavioural changes, or confusion (encephalopathy) - an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).
Slovenian: Neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov): - motnje v delovanju možganov, ki so lahko povezane z npr. zaspanostjo, spremembami obnašanja ali zmedenostjo (encefalopatija) - razširitev in oslabitev stene krvne žile ali raztrganina v steni krvne žile (anevrizme in disekcije arterij).
English: This indicates that sorafenib is neither an inhibitor nor an inducer of these cytochrome P450 isoenzymes.
Slovenian: To kaže, da sorafenib niti ne zavira niti ne inducira naštetih izoencimov citokroma P450.
English: Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
Slovenian: Zdravilo Nexavar je indicirano za zdravljenje bolnikov z napredovalim karcinomom ledvičnih celic, pri katerih je bilo predhodno zdravljenje z interferonom alfa ali interlevkinom-2 neuspešno ali pa tako zdravljenje za njih ni primerno.
English: Unchanged sorafenib, accounting for 51 % of the dose, was found in faeces but not in urine, indicating that biliary excretion of unchanged active substance might contribute to the elimination of sorafenib.
Slovenian: 51 % odmerka, so odkrili v blatu, ne pa tudi v seču, kar kaže na to, da nespremenjena učinkovina , ki se izloča z žolčem, morda prispeva k celokupnemu izločanju sorafeniba.
English: In study 5 (see section 5.1), 37% of subjects had dose interruption and 35% had dose reduction already in cycle 1 of sorafenib treatment.
Slovenian: V študiji 5 (glejte poglavje 5.1) so odmerjanje prenehali pri 37 % bolnikov, pri 35 % pa je bil odmerek zmanjšan že v prvem ciklu zdravljenja s sorafenibom.
English: Infections and infestations infection folliculitis
Slovenian: Infekcijske in parazitske bolezni okužbe folikulitis
English: België / Belgique / Belgien
Slovenian: België/Belgique/Belgien Bayer SA-NV
English: Caution is recommended when administering sorafenib with compounds that are metabolised/eliminated predominantly by the UGT1A1 (e.g. irinotecan) or UGT1A9 pathways (see section 4.5).
Slovenian: Previdnost je potrebna pri sočasni uporabi sorafeniba in učinkovin, ki se presnavljajo/izločajo predvsem z UGT1A1 (npr. irinotekan) ali UGT1A9 (glejte poglavje 4.5).
English: Most reports of hypocalcaemia were low grade.
Slovenian: Večinoma so poročali o hipokalciemiji nizke stopnje.
English: Patients taking concomitant warfarin or phenprocoumon should be monitored regularly for changes in prothrombin time, INR or clinical bleeding episodes (see sections 4.5 and 4.8).
Slovenian: Bolnike, ki sočasno jemljejo varfarin ali fenprokumon, je treba redno spremljati glede sprememb protrombinskega časa, vrednosti INR ali pojava klinično pomembnih krvavitev (glejte poglavji 4.5 in 4.8).
English: Nexavar is also used to treat kidney cancer (advanced renal cell carcinoma) at an advanced stage when standard therapy has not helped to stop your disease or is considered unsuitable.
Slovenian: Zdravilo Nexavar se uporablja tudi za zdravljenje bolnikov z rakom ledvic (napredovali karcinom ledvičnih celic), če standardno zdravljenje ni ustavilo napredovanja bolezni ali če se standardno zdravljenje ocenjuje kot neprimerno.
English: Table 3: Efficacy results from study 3 (study 100554) in hepatocellular carcinoma
Slovenian: Preglednica 3: Izsledki o učinkovitosti iz študije 3 (študija 100554) pri karcinomu jetrnih celic Parameter učinkovitosti sorafenib
English: Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
Slovenian: Zdravljenje traja tako dolgo, dokler je opaziti njegovo klinično korist oziroma dokler se ne pojavijo nesprejemljivi neželeni učinki.
English: If you are concerned, talk to a doctor.
Slovenian: Če ste negotovi, se posvetujte z zdravnikom.
English: Following progression, patients were allowed to receive open label sorafenib.
Slovenian: Po napredovanju so bolnikom dovolili prehod na sorafenib.
English: The clinical relevance of this finding is unknown (see below and section 4.4).
Slovenian: Klinični pomen te ugotovitve ni znan (glejte nadaljevanje in poglavje 4.4).
English: In cases of severe or persistent hypertension, or hypertensive crisis despite institution of antihypertensive therapy, permanent discontinuation of sorafenib should be considered (see section 4.8).
Slovenian: V primeru hude ali trdovratne hipertenzije oziroma hipertenzivne krize, kljub ustreznemu antihipertenzivnemu zdravljenju, je treba trajno prenehati zdravljenje s sorafenibom (glejte poglavje 4.8).
English: You will usually carry on taking this medicine as long as you are getting clinical benefits, and not suffering unacceptable side effects.
Slovenian: Zdravljenje s tem zdravilom običajno traja toliko časa, dokler je opaziti klinično korist oziroma dokler se vam ne pojavijo nesprejemljivi neželeni učinki zdravila.
English: If the patient intends to have a high-fat meal, sorafenib tablets should be taken at least 1 hour before or 2 hours after the meal.
Slovenian: Če namerava bolnik zaužiti mastno hrano, mora zdravilo vzeti najmanj eno uro pred obrokom hrane ali dve uri po njem.
English: The most important serious adverse reactions were myocardial infarction/ischaemia, gastrointestinal perforation, drug induced hepatitis, haemorrhage, and hypertension/hypertensive crisis.
Slovenian: Najbolj pomembni resni neželeni učinki so bili srčni infarkt/ishemija, gastrointestinalna perforacija, hepatitis zaradi zdravil, krvavitve in hipertenzija/hipertenzivna kriza.
English: Most reports of hypocalcaemia were low grade (CTCAE Grade 1 and 2).
Slovenian: V večini poročil je bila hipokalciemija nizke stopnje (1. in 2. stopnje po CTCAE).
English: Demographics and baseline disease characteristics were comparable between the sorafenib and the placebo group with regard to ECOG status (status 0: 54 % vs. 54 %; status 1: 38 % vs. 39 %; status 2: 8 % vs. 7 %), TNM stage (stage I: <1 % vs. <1 %; stage II: 10.4 % vs. 8.3 %; stage III: 37.8 % vs. 43.6 %; stage IV: 50.8 % vs. 46.9 %), and BCLC stage (stage B: 18.1 % vs. 16.8 %; stage C: 81.6 % vs. 83.2 %; stage D: < 1 % vs. 0 %).
Slovenian: Demografske značilnosti in izhodiščne značilnosti bolezni so bile med skupino bolnikov, ki so se zdravila s sorafenibom in skupino bolnikov, ki so prejemali placebo primerljive glede na stanje po ECOG (stanje 0: 54 % v primerjavi s 54 %; stanje 1: 38 % v primerjavi z 39 %; stanje 2: 8 % v primerjavi s 7 %), stadij TNM (stadij I: < 1 % v primerjavi z < 1 %; stadij II: 10,4 % v primerjavi z 8,3 %; stadij III: 37,8 % v primerjavi s 43,6 %; stadij IV: 50,8 % v primerjavi s 46,9 %) in stadij BCLC (stadij B: 18,1 % v primerjavi s 16,8 %; stadij C: 81,6 % v primerjavi s 83,2 %; stadij D: < 1 % v primerjavi z 0 %).
English: Cases of renal failure have been reported.
Slovenian: Poročali so o primerih odpovedi ledvic.
English: No data is available in patients requiring dialysis (see section 5.2).
Slovenian: Podatkov o bolnikih, ki potrebujejo dializo, ni na voljo (glejte poglavje 5.2).
English: QT interval prolongation
Slovenian: podaljšanje intervala QT
English: A post-hoc subgroup analysis by thyroid carcinoma symptoms at baseline showed a treatment effect for PFS in favour of sorafenib over placebo for both symptomatic and asymptomatic patients.
Slovenian: Analiza post-hoc podskupine glede na simptome karcinoma ščitnice na začetku zdravljenja je pokazala učinek zdravljenja na PFS v korist sorafeniba v primerjavi s placebom tako pri simptomatskih kot asimptomatskih bolnikih.
English: - If you have thyroid cancer.
Slovenian: - če imate raka ščitnice.
English: Nexavar is a so-called multikinase inhibitor.
Slovenian: Zdravilo Nexavar je multikinazni zaviralec.
English: Your doctor will monitor blood calcium and thyroid hormone levels.
Slovenian: Zdravnik bo spremljal vrednosti kalcija v krvi in vrednosti ščitničnega hormona.
English: Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro.
Slovenian: Sorafenib je multikinazni zaviralec, ki zmanjša proliferacijo tumorskih celic in vitro.
English: Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß).
Slovenian: Sorafenib zavira delovanje različnih tarč v tumorski celici (CRAF, BRAF, V600E BRAF, c-KIT in FLT-3) in tumorskem žilju (CRAF, VEGFR-2, VEGFR-3 in PDGFR-ß).
English: In a clinical pharmacology study (single dose of 400 mg sorafenib), no relationship was observed between sorafenib exposure and renal function in subjects with normal renal function, mild, moderate or severe renal impairment.
Slovenian: V študiji klinične farmakologije (posamezen odmerek 400 mg sorafeniba) niso opazili povezanosti med izpostavljenostjo sorafenibu in delovanjem ledvic niti pri bolnikih z normalnim delovanjem ledvic niti pri tistih z blago, zmerno ali hudo okvaro ledvic.
English: Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Slovenian: Zdravilo Nexavar je indicirano za zdravljenje bolnikov s progresivnim, lokalno napredovalim ali metastatskim, diferenciranim (papilarnim/folikularnim/Hürthlejevim) karcinomom ščitnice, odpornim na radioaktivni jod.
English: Respiratory, thoracic and mediastinal disorders rhinorrhoea dysphonia interstitial lung disease-like events* (pneumonitis, radiation pneumonitis, acute respiratory distress, etc. )
Slovenian: Bolezni dihal, prsnega koša in mediastinalne ga prostora rinoreja disfonija intersticijski pljučni bolezni podobna stanja* (pljučnica, pljučnica zaradi obsevanja, akutna dihalna stiska, itd.)
English: However, in clinical pharmacokinetic studies, concomitant administration of sorafenib 400 mg twice daily with cyclophosphamide, a CYP2B6 substrate, or paclitaxel, a CYP2C8 substrate, did not result in a clinically meaningful inhibition.
Slovenian: V kliničnih farmakokinetičnih študijah, sočasna uporaba sorafeniba 400 mg dvakrat na dan s ciklofosfamidom, substratom CYP2B6 ali paklitakselom, substratom CYP2C8, ni povzročila klinično pomembnega zaviranja.
English: Very common:
Slovenian: Zelo pogosti
English: High Risk Patients, according to MSKCC (Memorial Sloan Kettering Cancer Center) prognostic group, were not included in the phase III clinical study in renal cell carcinoma (see study 1 in section 5.1), and benefit-risk in these patients has not been evaluated.
Slovenian: V klinično študijo III. faze pri bolnikih s karcinomom ledvičnih celic (glejte podatke o študiji 1 v poglavju 5.1) niso bili vključeni bolniki z velikim tveganjem glede na prognostične kriterije MSKCC (Memorial Sloan Kettering Cancer Center); razmerje med koristmi in tveganji pri teh bolnikih ni bilo ocenjeno.
English: Children and adolescents have not yet been tested with Nexavar.
Slovenian: Otroci in mladostniki Uporabe zdravila Nexavar pri otrocih in mladostnikih niso preskušali.
English: Exploratory subgroup analyses suggested that patients with distant metastases at baseline derived a less pronounced treatment effect.
Slovenian: Analiza podskupin je nakazala, da je pri bolnikih s prisotnimi oddaljenimi zasevki na začetku zdravljenja učinek zdravljenja manj izrazit.
English: Metabolism and nutrition disorders anorexia hypophosphataemia hypocalcaemia hypokalaemia hyponatraemia hypoglycaemia dehydration
Slovenian: Presnovne in prehranske motnje anoreksija hipofosfatemija hipokalciemija hipokaliemija hiponatriemija hipoglikemija dehidracija
English: The overall response rate (CR + partial response (PR) per independent radiological assessment was higher in the sorafenib group (24 patients, 12.2%) than in the placebo group (1 patient, 0.5%), one-sided p<0.0001.
Slovenian: Stopnja celokupnega odziva (CR + delni odziv (PR, partial response), ovrednotena z neodvisno oceno radioloških posnetkov je bila višja za skupino bolnikov, ki so se zdravili s sorafenibom (24 bolnikov, 12,2 %) kot za skupino bolnikov, ki so prejemali placebo (1 bolnik, 0,5 %), enostranski p < 0,0001.
English: In the event of suspected overdose sorafenib should be withheld and supportive care instituted where necessary.
Slovenian: V primeru suma na preveliko odmerjanje je treba zdravljenje s sorafenibom prenehati in začeti z ustreznim podpornim zdravljenjem, če je potrebno.
English: Taking too much Nexavar makes side effects more likely or more severe, especially diarrhoea and skin reactions.
Slovenian: Po zaužitju prevelikega odmerka zdravila Nexavar je pojav neželenih učinkov bolj verjeten oziroma so ti hujši, še posebej driska in kožne reakcije.
English: Concomitant administration of sorafenib and midazolam, dextromethorphan or omeprazole, which are substrates for cytochromes CYP3A4, CYP2D6 and CYP2C19 respectively, did not alter the exposure of these agents.
Slovenian: Sočasna uporaba sorafeniba in midazolama, dekstrometorfana ali omeprazola, ki so substrati citokromov CYP3A4, CYP2D6 oziroma CYP2C19, ne vpliva na izpostavljenost tem snovem.
English: What do you need to know before you take Nexavar Do not take Nexavar
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Nexavar